Supersensitivity to @entity1063 contributes to certain @entity455 (e.g., @entity101 ) and chronic @entity9 conditions (e.g., complex regional @entity158 ). We aimed to develop a procedure for inducing adrenergic supersensitivity that could be used to investigate the role of @entity2661 in these clinical conditions. In the first study, three doses of @entity2997 were administered by iontophoresis to separate small patches of skin in the forearm of healthy @entity1 volunteers. Four to five hours later. the vasoconstrictor response to the adrenergic releasing agent @entity6114 was inhibited in a dose-dependent manner by iontophoretic pretreatment with @entity2997 , indicating that @entity2997 had depleted endogenous adrenergic stores. In a second study, @entity2997 and saline were administered by iontophoresis four times over approximately 2 weeks at separate sites in the forearm. One to two days after the final pretreatment, vasoconstriction to the iontophoresis of a weak dose of @entity1063 was enhanced at sites pretreated with @entity2997 . To investigate the effect of @entity2997 pretreatment on thermal @entity1931 . the experimental sites were sensitized to heat by the topical application of 0.6% @entity2951 . Both before and after the application of @entity2951 , the heat- @entity158 threshold and heat- @entity158 ratings to suprathreshold stimulation were similar at sites pretreated for 2 weeks with @entity2997 or saline. However, after the iontophoresis of @entity1063 , thermal @entity1931 was greater at the @entity2997 -pretreated site than the saline pretreated site. These observations indicate that prolonged depletion of adrenergic stores by @entity2997 induces adrenergic supersensitivity in cutaneous vessels, and that adrenergic supersensitivity enhances thermal @entity1931 in the presence of @entity1063 .

Vascular and nociceptive effects of localized prolonged sympathetic blockade in XXXX skin.

@entity2997 :: ('MESH:D006145', 'Chemical') :: ['guanethidine'] @entity1 :: ('9606', 'Species') :: ['human'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disorders'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['hyperalgesia'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity2951 :: ('MESH:D002211', 'Chemical') :: ['capsaicin'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'pain syndrome'] @entity2661 :: ('MESH:D002395', 'Chemical') :: ['catecholamines'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain'] @entity6114 :: ('MESH:D014439', 'Chemical') :: ['tyramine']
@entity1 :: (9606,Species) :: ['human']
